V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Inclusion Criteria: * Patients must have stages II, III, or IV breast, colorectal, ovaria, of non-small cell lung cancer * Patients will either be disease free following primary therapy or have advanced disease with a durable response (\>3 months) after standard therapy * Tumor antigen HER-2 and/or CEA must be measurable in the blood or detected by Immunohistochemistry staining of the biopsies obtained from the primary tumor or metastasis Exclusion Criteria: * Patients with prior treatment with any HER-2 and/or CEA containing vaccine * Patients who have significant cardiac disease * Patients with autoimmune disorders * Patients who are pregnant or lactating